Gilead Sciences Inc. (NASDAQ:GILD) registered a 0.31% increase, still its new closing price is 2.49% up from the company’s 1 year high of 101.25.It posted -3.84% losses in previous 5 sessions and is now the subject of 11 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 8 buy or better ratings. The 28 stock analysts following this company have an average price target at $95.01, with individual PT in the $74.29-$118.00 range. The shares moved at $72.13, implying that brokerage firms see shares losing about -17.91% in twelve months time.

Gilead Sciences Inc. (GILD) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 0.73% rise year to date. A Executive Chairman at Gilead Sciences Inc. (GILD) offloaded shares in a transaction closed on Tuesday January 03, 2017. MARTIN JOHN C sold 73,337 shares in the company at $73.59 each and collected $5,396,001 in proceeds. MARTIN JOHN C now owns 3,131,096 shares in the company after this transaction. A Executive Chairman in the company, MARTIN JOHN C, disclosed a transaction on Thursday December 01, 2016 that ended up generating $7,333,000 from the sale of 100,000 shares at $73.33 per share.

Gilead Sciences Inc. (NASDAQ:GILD) Upcoming Results on Tap

Gilead Sciences Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $2.60 in that period. Sales during the quarter are predicted to arrive at $7.1 billion.

Earnings surprise history: Last quarter, the company posted approximately $7.5 billion in revenue and EPS of $2.75. The mean forecast was for $7.45 billion and $2.86 a share, respectively. One quarter earlier, revenue for the stock was at $7.78 billion, with earnings at $3.08/share.

Gilead Sciences Inc. (GILD) Brokerage Update

Gilead Sciences Inc. (GILD) is in Leerink Partners’s research list so their analyst rating change is noteworthy. These shares were downgraded to Mkt Perform from Outperform by Leerink Partners, according to news reported on Tuesday September 27, 2016.Another important research note was issued by Jefferies on Tuesday September 06, 2016.The firm upgraded GILD to Buy from Hold. Over the last six months and over the last three months, the shares of Gilead Sciences Inc. (GILD), have changed -14.52% and -0.06%, respectively.

Gilead Sciences Inc. (NASDAQ:GILD) on January 11, 2017 announced that the European Commission has granted marketing authorization for Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg).

The marketing authorization allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland.

TAF is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 245 mg, but at one-tenth the dose. Data show that because TAF has greater plasma stability and more efficiently delivers tenofovir to hepatocytes (cells of the liver) compared to TDF, it can be given at a lower dose, which means there is less tenofovir in the bloodstream. By reducing exposure to tenofovir, TAF is associated with improved renal and bone laboratory safety parameters compared to TDF in clinical trials.

TAF’s approval is supported by 48-week data from two international Phase 3 studies (Studies 108 and 110) in 1,298 adult chronic HBV patients. Study 108 randomized 425 HBeAg-negative patients to receive either TAF or TDF, and Study 110 randomized 873 HBeAg-positive patients to receive either TAF or TDF. Both studies met their primary endpoint of non-inferiority to TDF based on the percentage of patients with chronic hepatitis B with plasma HBV DNA levels below 29 IU/mL at 48 weeks of therapy. Patients in the TAF arm of the trials also experienced numerically higher rates of normalization of blood serum alanine aminotransferase (ALT) levels. Both studies showed TAF and TDF to be well-tolerated by patients and discontinuations due to adverse events were 1% and 1.2%, respectively. The most common reported adverse events with TAF were diarrhea, vomiting, nausea, abdominal pain, abdominal distension, flatulence, fatigue, headache, dizziness, rash, pruritus, increased ALT and arthralgia.

While the primary efficacy assessment was performed at week 48, data show that at week 72 viral suppression as well as biochemical responses were maintained with continued TAF treatment. The safety assessment includes analyses performed at both week 48 and week 72 of treatment (median duration of exposure of 88 weeks), and safety endpoints included changes from baseline in bone mineral density at the hip and spine, and changes from baseline in serum creatinine and in eGFR, key indicators of renal health. In both studies, at weeks 48 and 72, changes in renal and bone laboratory safety parameters favored the TAF treatment groups.

Vemlidy was approved by the U.S. Food and Drug Administration on November 10, 2016 for the treatment of chronic HBV infection in adults with compensated liver disease, and by the Japanese Ministry of Health, Labour and Welfare on December 19, 2016 for the suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function.